CD274 and renal cell carcinoma: Positive Phase III studies have led to recent approvals by the FDA for dual PD-1/PD-L1 and anti-VEGF combinations in RCC (pembrolizumab plus axitinib, and avelumab plus axitinib), endometrial carcinoma (pembrolizumab plus lenvatinib), non-squamous NSCLC (atezolizumab, bevacizumab and chemotherapy), and HCC, suggesting a potential broad clinical utility of this combination strategy (104, 105, 107, 109–111).